Sagar Lonial, MD, discusses the expanding potential uses of cereblon E3 ligase modulators (CELMoDs) in combination with T-cell redirection therapies in multiple myeloma. In a forward-looking interview ...

In an interview, Vincent Ma, MD, explores the clinical utility of circulating tumor DNA dynamics to assess early outcomes in ...

Report finds hospitals price the same cancer drugs up to 2000x apart, worsening financial toxicity and intensifying demands for real transparency.

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance. In a recent discussion, ...

Leapman, MD, MHS, associate professor of urology at Yale University, addresses a critical and often overlooked limitation in the current landscape of prostate cancer biomarkers: while these tools have ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates. In an interview with Targeted Oncology, Hua-Jay “Jeff” ...

DNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes. In an interview with Targeted Oncology, Rutika Mehta, MD, ...

In this interview, Sagar Lonial, MD, discussed the EXCALIBER-RRMM trial design and the potential role of iberdomide in the ...

In an interview with Targeted Oncology, Natalie Berger, MD, hematologist and oncologist at the New York Presbyterian Medical Group, weighed the biggest hurdles she witnesses in HPV vaccination and ...

Enrollment has been completed for a phase 2a randomized clinical trial evaluating the investigational microbiome therapeutic EBX-102-02 in patients undergoing allogeneic hematopoietic stem cell ...

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment. For oncology clinicians, the Liver Imaging-Reporting and Data System ...